Current perspectives on FTY720

Abstract

The search for effective immunosuppressants with fewer side effects continues not only for transplantation, but also for autoimmune diseases. With a novel mechanism of action (sphingosine-1 receptor modulation), oral FTY720 (fingolimod) has the potential to address this need. FTY720 has been preclinically tested with promising results in transplantation and autoimmune disease models. Phase I studies explored the pharmacokinetics and pharmacodynamics of this novel therapeutic concept. Recently, the surprising results of two sister Phase III studies in de novo renal transplant patients, as well as a Phase II study in patients with relapsing multiple sclerosis, were published. This review discusses these findings as well as their implications for the future of sphingosine-1 receptor modulation.

Keywords::

• fingolimod
• FTY
• FTY720
• multiple sclerosis
• renal transplantation
• sphingosine-1-phosphate

Disclosure

S Martini is a recipient of a research grant from Novartis Pharma. T Böhler is a recipient of a grant from Novartis Pharma France. K Budde served as a consultant for and/or have received research grants from Novartis Pharma.